LEGACY Study The Rise of New Weight Loss Medications Originally developed to treat type 2 diabetes , drugs like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) are now licensed for the treatment of obesity
Clinical trial evidence on tirzepatide and thyroid safety The most important evidence for anyone evaluating tirzepatide with thyroid nodules comes from large-scale clinical trials
Hold the needle in place
NICE recommends Wegovy for adults who: Have a body mass index (BMI) of 35 kg/m or more (or 30 kg/m or more for people from some minority ethnic groups), or Have a BMI of 3034.9 kg/m (or 27.529.9 kg/m for people from some minority ethnic groups) with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, obstructive sleep apnoea, or cardiovascular disease) Are participating in a specialist weight management service that provides dietary advice, physical activity support, and behavioural interventions Treatment should be discontinued after a maximum of 2 years within the specialist weight management service
Understanding semaglutide dosing is critical for patient safety and treatment success
While these therapeutic benefits are significant, they come with specific safety measures to ensure proper use
.webp)
.jpg)
